Eileen M. O’Reilly holds the Winthrop Rockefeller Endowed Chair in Medical Oncology at Memorial Sloan Kettering (MSK). She serves as the Section Head for Hepatopancreaticobiliary/ Neuroendocrine Cancers, Gastrointestinal Oncology Service, Co-Director for Medical Initiatives at the David M. Rubenstein Center for Pancreatic Cancer and is an Attending Physician and Member at MSK and Professor of Medicine at Weill Cornell Medical College.

 

Dr. O’Reilly received her medical degree at Trinity College in Ireland. She completed her postgraduate training in Ireland and subsequent Hematology/Oncology Fellowship training at MSK. Dr. O’Reilly is a clinical scientist whose research focus involves integration of molecular and genetic-based therapies for pancreas cancer along with development of adjuvant and neoadjuvant treatments and identification of biomarkers for therapy selection. Dr. O’Reilly teaches and mentors junior faculty, oncology fellows, residents and medical/other students and has numerous teaching and other awards. Dr. O’Reilly is the Principal Investigator of multiple phase I, II, III trials in pancreas cancer and has authored/co-authored ~425 articles, editorials, and book chapters and has a H-index of 100. She serves as an Associate Editor for the Journal of Clinical Oncology and Senior Editor for several other journals and has served on multiple grant review panels including, for the American Society of Clinical Oncology (ASCO), American Association of Cancer Research (AACR), NIH, DOD, and various international entities. She is PI of the MSK Pancreas Specialized Program in Oncology Research Excellence (SPORE), an NCI funded team science grant. Dr. O’Reilly is the recipient of numerous awards including the Burkitt Medal (TCD) in 2022, and Giants of Cancer Care GI Oncology, 2023.

 

Dr. O’Reilly’s other responsibilities include Chair of the Human Research Protection Program and Institutional Review & Privacy Board (IRB). Nationally, Dr. O’Reilly is Co-Chair of the NCI Alliance Co-Operative Group Gastrointestinal Cancers Committee and serves on the NCI Gastrointestinal Cancers Steering Committee (GISC) and serves in leadership roles in several advocacy organizations including the National Pancreas Foundation, Hirshberg Foundation and Pancreas Cancer Action Network.

Prof. Eileen O’Reilly has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Research Funding to institution: Genentech/Roche, BioNTech, AstraZeneca, Arcus, Elicio, Parker Institute, NIH/NCI, Digestive Care, Break Through Cancer, Agenus, Amgen, Revolution Medicines

 

Consulting/DSMB (mostly uncompensated): Arcus, AstraZeneca, Ability Pharma, Alligator BioSciences, Agenus, BioNTech, Ipsen, Ikena, Merck, Moma Therapeutics, Novartis, Leap Therapeutics, Astellas, BMS, Revolution Medicines, Regeneron, Tango.

 

Travel: BioNTech